Abstract
The real promise of the metabolic syndrome concept was the opportunity to elucidate
a singular common mechanism for its component abnormalities and consequently a singular
therapy. That promise has not produced. This relates to the following considerations:
(1) metabolic syndrome remains a syndrome not a disease, (2) its diagnosis offers
little more than what can be determined by measuring waist circumference, (3) risk
assessment is not improved by the diagnosis of metabolic syndrome, (4) the diagnosis
of metabolic syndrome does not impact the treatment of each component of the syndrome,
and (5) there is no effective therapy for metabolic syndrome in its entirety.
Résumé
La véritable promesse du concept de syndrome métabolique était la possibilité d’élucider
le mécanisme commun particulier des anomalies de ses composantes et par conséquent
mettre au point un traitement particulier. Cette promesse ne s’est pas concrétisée.
Cela est fondé sur les considérations suivantes : 1) le syndrome métabolique est bien
un syndrome, et non une maladie; 2) son diagnostic offre un peu plus que ce que la
mesure du tour de taille permet de déterminer; 3) le diagnostic du syndrome métabolique
n’améliore pas l’évaluation du risque; 4) le diagnostic du syndrome métabolique n’a
pas de répercussion sur le traitement de chacune des composantes du syndrome; 5) aucun
traitement efficace n’existe pour traiter globalement le syndrome métabolique.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Banting lecture 1988. Role of insulin resistance in human disease.Diabetes. 1988; 37: 1595-1607
Bastien M, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014;56:369-81.
Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-39.
- Feast or famine: the sympathetic nervous system response to nutrient intake.Cell Mol Neurobiol. 2006; 26: 497-508
- Nonesterified fatty acids in blood pressure control and cardiovascular complications.Curr Hypertens Rep. 2001; 3: 107-116
- Hemodynamic actions of insulin.Am J Physiol. 1994; 267: E187-E202
- Insulin-mediated vasodilation: impairment with increased blood pressure and body mass.Lancet. 1993; 342: 707-709
- Perivascular adipose tissue in vascular function and disease: a review of current research and animal models.Arterioscler Thromb Vasc Biol. 2014; 34: 1621-1630
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.Diabet Med. 1998; 15: 539-553
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).JAMA. 2001; 285: 2486-2497
- Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.Circulation. 2005; 112: 2735-2752
- The metabolic syndrome—a new worldwide definition.Lancet. 2005; 366: 1059-1062
Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.
- ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.Can J Cardiol. 2000; 16: 41E-44E
- Issues in hypertension: drug tolerability and special populations.Am J Hypertens. 2001; 14: 231S-236S
- Bariatric surgery: effects on the metabolic complications of obesity.Curr Atheroscler Rep. 2012; 14: 95-100
- Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.Dermatol Clin. 2015; 33: 41-55
- Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.Am J Med. 2014; 127: 1148-1153
Article info
Publication history
Accepted:
December 31,
2014
Received:
December 30,
2014
Footnotes
See article by Fitchett, pages 596-600 of this issue.
See page 603 for disclosure information.
Identification
Copyright
© 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
